Patent application number | Description | Published |
20090217391 | T1R3 A NOVEL TASTE RECEPTOR - The present invention relates to the discovery, identification and characterization of a receptor protein, referred to herein as T1R3, which is expressed in taste receptor cells and associated with the perception of bitter and sweet taste. The invention encompasses T1R3 nucleotides, host cell expression systems, T1R3 proteins, fusion protein, transgenic animals that express a T1R3 transgene, and recombinant “knock-out” animals that do not express T1R3. The invention further relates to methods for identifying modulators of the T1R3-mediated taste response and the use of such modulators to either inhibit or promote the perception of bitterness or sweetness. The modulators of T1R3 activity may be used as flavor enhancers in food, beverages and pharmaceuticals. | 08-27-2009 |
20110123984 | FAM26C POLYMORPHISMS AND USE THEREOF FOR THE DIAGNOSTIC AND TREATMENT OF LATE ONSET ALZHEIMER'S DISEASE - Provided are methods of determining the likelihood that a subject will be diagnosed with Alzheimer's disease. Also provided are isolated and purified mammalian CALHM I, CALHM2, and CALHM3 proteins, vectors comprising a nucleic acid sequence encoding the CALHM 1, CALHM2, and CALHM3 proteins, and mammalian cells transfected with the vectors. Additionally, methods of affecting Ca2+ levels in a mammalian cell are provided. Further provided are methods of screening a test compound for the ability to alter calcium homeostasis in mammalian cells. Also, methods of affecting Ca2+levels in mammalian cells are provided. Additionally provided are methods of screening a test compound for the ability to inhibit ERK I/2 phosphorylation in a mammalian cell. Further provided are methods of screening a test compound for the ability to inhibit amyloid-beta peptide accumulation in a mammalian cell or biological fluid. Also provided are methods of screening for a test compound that may affect Alzheimer's disease. | 05-26-2011 |
Patent application number | Description | Published |
20090081211 | C3b antibodies and methods for the prevention and treatment of complement-associated disorders - The present invention concerns antibodies to C3b and the prevention and treatment of complement-associated disorder using such antibodies. | 03-26-2009 |
20090123469 | Anti-factor B antibodies and their uses - The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of factor B antagonists. | 05-14-2009 |
20090162356 | CRIg antagonists - The present invention concerns blocking antibodies specifically binding a recently discovered macrophage specific receptor, CRIg, and their use to prevent cellular entry of intracellular pathogens, such as viruses, bacteria or parasites as well as for prevention of unwanted clearance of erythrocytes and platelets. | 06-25-2009 |
20090269338 | HUMANIZED ANTI-FACTOR D ANTIBODIES AND USES THEREOF - The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease. | 10-29-2009 |
20100150908 | Affinity matured CRIg variants - The present invention concerns affinity matured CRIg variants. In particular, the invention concerns CRIg variants having increased binding affinity to C3b and retaining selective binding to C3b over C3. | 06-17-2010 |
20100291694 | Crystal Structure of CRIg and C3B:CRIg Complex - The present invention concerns determination of the crystal structure of the macrophage specific receptor, CRIg (earlier referred to as STIgMA), and its complex with the C3b and C3c subunits of complement C3 (C3b:CRIg and C3c:CRIg complexes). The invention further concerns the use of the crystal structure of CRIg or the C3b:CRIg complex to screen for and identify molecules structurally and/or functionally related to CRIg, including CRIg agonists and antagonists. | 11-18-2010 |
20110165648 | Co-crystal structure of factor D and anti-factor D antibody - The present invention is directed towards the co-crystal structure of Factor D and an anti-Factor D antibody or an antigen binding fragment thereof. | 07-07-2011 |
20110282034 | PREVENTION AND TREATMENT OF COMPLEMENT-ASSOCIATED EYE CONDITIONS - The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists. | 11-17-2011 |
20120128674 | C3b antibodies and methods for the prevention and treatment of complement-associated disorders - The present invention concerns antibodies to C3b and the prevention and treatment of complement-associated disorder using such antibodies. | 05-24-2012 |
20120128698 | DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DEMYELINATING DISEASES - The present invention concerns the diagnosis and treatment of autoimmune demyelinating diseases, such as multiple sclerosis (MS), by means of a CLM-I agonist. | 05-24-2012 |
20120230997 | Anti-factor B antibodies and their uses - The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of factor B antagonists. | 09-13-2012 |
20120328613 | HUMANIZED ANTI-FACTOR D ANTIBODIES AND USES THEREOF - The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease. | 12-27-2012 |
20130129743 | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE - The invention provides anti-HtrA1 antibodies and methods of using the same. | 05-23-2013 |
20130302333 | PREVENTION AND TREATMENT OF COMPLEMENT-ASSOCIATED EYE CONDITIONS - The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists. | 11-14-2013 |
20140065137 | HUMANIZED ANTI-FACTOR D ANTIBODIES AND USES THEREOF - The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease. | 03-06-2014 |
20140212433 | Humanized Anti-Factor D Antibodies And Uses Thereof - The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease. | 07-31-2014 |